PHARMACOECONOMIC OF CKD-MBD TREATMENT: LITERATURE REVIEW
https://doi.org/10.24884/1561-6274-2018-22-1-38-51
Abstract
In the majority of hemodialysis patients there are mineral and bone disorders, of which the most common is secondary hyperparathyroidism. A number of new products such as paricalcitol, cinacalcet and some phosphate-binding drugs have been developed and introduced in clinical practice in the past decade in order to correct this life-threatening complication of chronic kidney disease. A number of pharmacoeconomic studies have been carried out to determine the cost-effectiveness of appointing certain drugs due to increasing of the public expenditure in this therapy in many countries, including Russia. In this review, we consider a brief analysis of the methods for evaluating the profitability of medicines and the results of recent studies devoted to the evaluation of the cost-effectiveness of CKD-MBD treatment.
About the Authors
K. A. Vishnevskii
Saint Petersburg City hospital №15
Russian Federation
Russian Federation
Konstantin A. Vishnevskii – PhD, head of hemodialysis unit.
198205, St.-Petersburg, Avangardnaya str. 4, (812)7369342
A. Yu. Zemchenkov
Pavlov First Saint Petersburg State Medical University; North-Western I.I.Mechnikov State medical university
Russian Federation
Russian Federation
Alexander Y. Zemchenkov – PhD, nephrology and dialysis chair FSP I.P. Pavlov SMU, internal diseases and nephrology chair NW I.I. Mechnikov SMU.
197022, St.-Petersburg, L`va Tolstogo str. 17; 191015, St.Petersburg, Kirochnaya str. 41, (812)2757328
R. P. Gerasimchuk
North-Western I.I.Mechnikov State medical university
Russian Federation
Russian Federation
Roman P. Gerasimchuk – PhD, internal diseases and nephrology chair NW I.I. Mechnikov SMU.
191015, St.-Petersburg, Kirochnaya str. 41, (812)2757328
A. Sh. Rumyantsev
Saint Petersburg State University; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
AlexanderS. Rumyantsev- MD, PhD, DMedSci, FSPI.P. PavlovSMU; DepartmentofFacultytherapySPU.
197022, St.-Petersburg, L`va Tolstogo str. 17; 199034, St.-Petersburg, Universitetskaya emb. 7/9, (812)2340165A. V. Smirnov
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Alexey V. Smirnov - MD, PhD, DMedSci, head of propedeutics of internal diseases chair
197022, St.-Petersburg, L`va Tolstogo str. 17, (812)2340165
S. A. Partsernyak
Saint Petersburg City hospital №15
Russian Federation
Russian Federation
Sergey A. Partsernyak - MD, PhD, DMedSci, Deputy Chief of therapy City hospital №15; Hospital Therapy and Cardiology Chair named after M.S. Kushakovsky NW I.I.Mechnikov SMU.
198205, St.-Petersburg, Avangardnaya str. 4; 191015, St.-Petersburg, Kirochnaya str. 41, (812) 7350766
P. V. Maryutin
Saint Petersburg City hospital №15
Russian Federation
Russian Federation
Petr V. Maryutin - PhD, PhD, Acting Chief Physician City hospital №15.
198205, St.-Petersburg, Avangardnaya str. 4, (812) 7350766
References
1. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26(6): 1948–1955
2. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52(3): 519–530
3. Goto S, Komaba H, Fukagawa M, Nishi S. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney Int Suppl 2013; 3(5): 457-461
4. Tokumoto M, Taniguchi M, Matsuo D et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther Apher Dial 2005; 9 Suppl 1: 27-34
5. Mejía N, Roman-García P, Miar AB et al. Chronic kidney disease –mineral and bone disorder: a complex scenario. Nefrologia 2011; 31:514–519
6. Kuro-O M. Phosphate and Klotho. Kidney Int 2011;79121: 20-23. doi:10.1038/ki.2011.26
7. Ketteler M, Wüthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J 2013;6(2):128–136
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):1–130
9. Sprague S, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490
10. Coyne DW, Grieff M, Ahya SN et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283-1288
11. Block GA, Bushinsky DA, Cheng S et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017;317(2):156-164. doi: 10.1001/jama.2016.19468
12. Floege J, Covic AC, Ketteler M et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015;30(6):1037-1046. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16
13. Hutchison AJ, Wilson RJ, Garafola S, Copley JB. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) 2016;21(12):987-994. doi: 10.1111/nep.12864
14. Герасимчук РП, Земченков АЮ, Новокшонов КЮ и др. Влияние паратиреоидэктомии на динамику лабораторных показателей МКН ХБП и выживаемость пациентов, получающих заместительную терапию диализом в Санкт-Петербурге. Нефрология и диализ 2016; 18(1): 40-49.[Gerasimchuk RP, Zemchenkov AYu, Novokshonov KY et al. The impact of parathyroidectomy on the dynamics of CKD-MBD laboratory parameters and survival of dialysis patients in St.-Petersburg. Nephrology and dialysis 2016; 18(1): 40-49]
15. Huybrechts KF, Caro JJ, Wilson DA et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005; 8: 549–561
16. Thompson M, Bartko-Winters S, Bernard L et al. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ 2013; 16: 744–755
17. Vegter S, Tolley K, Keith MS et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health 2011; 14: 852–858
18. Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012; 15: 509–520
19. Nuijten M, Andress DL, Marx SE et al. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig 2010; 30: 545–557
20. Нюйтен М, Рудакова АВ, Маршалл T. Эффективность затрат на парикальцитол и комбинацию цинакальцета и неселективных препаратов витамина D при хронической болезни почек VД стадии в Российской Федерации. Нефрология 2014; 18(6): 64-70. [Nuijten M, Rudakova A, Marshall T. Health economic evaluation of paricalcitol and combination of cinacalcet with non-selective vitamin D in patients with chronic kidney disease 5D stage in Russian Federation. Nephrology (SaintPetersburg) 2014;18(6):64-70]
21. Угрехелидзе ДТ, Куликов АЮ. Фармакоэкономический анализ лекарственного средства вельфоро® 500 (комплекс β-железа (III) оксигидроксида, сахарозы и крахмала) в лечении гиперфосфатемии у пациентов с хронической болезнью почек. Фармакоэкономика: теория и практика 2016; 4(1): 176-182 [Ugrekhelidze DT, Kulikov AYU. Farmakoekonomicheskiy analiz lekarstvennogo sredstva velforo® 500 (kompleks b-zheleza (III) oksigidroksida, sakharozy i krakhmala) v lechenii giperfosfatemii u patsiyentov s khronicheskoy bolezn’yun’yu pochek. Farmakoekonomika: teoriya i praktika 2016; 4(1): 176-182]
22. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2010. Amsterdam: Academic Medical Center, Department of Medical Informatics, 2012
23. United States Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
24. Nakai S, Watanabe Y, Masakane I et al. Overview of regular dialysis treatment in Japan (as of December 31, 2011). J Jpn Soc Dial Ther 2013;46: 1–76
25. Бикбов БТ, Томилина НА. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998–2011 гг. (Отчет по данным Российского регистра заместительной почечной терапии. Часть первая). Нефрология и диализ 2014; 16(1): 11-127. [Bikbov BT, Tomilina NA. Renal replacement therapy for ESRD patients in Russian Federation, 1998–2011 Report of Russian RRT Registry. Part 1. Nephrology and dialysis 2014; 16(1): 11-127]
26. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007;18(10):2644–2648
27. Fukuhara S, Yamazaki C, Hayashino Y et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ 2007; 7: 217–231
28. Ranasinghe P, Perera YS, Makarim MF et al. The costs in provision of haemodialysis in a developing country: a multicentered study. BMC Nephrol 2011;12:42. doi: 10.1186/1471-2369-12-42
29. Reddy YN, Sundaram V, Abraham G et al. Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective. Int J Nephrol Renovasc Dis 2014;7:391-399. doi: 10.2147/IJNRD.S49933.eCollection 2014
30. Sharma A, Ketteler M, Marshall TS et al. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. J Med Econ 2013;16(9):1129-1136. doi: 10.3111/13696998.2013.823092. Epub 2013 Jul 24
31. Бикбов БТ, Томилина НА. Заместительная терапия больных с хронической почечной недостаточностью методами перитонеального диализа и трансплантации почки в Российской Федерации в 1998–2011 г. (Отчет по данным Российского регистра заместительной почечной терапии. Часть вторая). Нефрология и диализ 2014; 16(2): 192-227 [Bikbov BT, Tomilina NA. Renal Replacement Therapy for ESRD patients with CAPD and kidney transplantation in Russian Federation, 1998–2011. Report of Russian RRT Registry, Part 2. Nephrology and dialysis 2014; 16(2): 192-227]
32. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care 2008;35(2):329–344. doi: 10.1016/j.pop.2008.01.008
33. Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002;17(Suppl 5):28–31
34. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208–2218
35. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007;13(5):397–411
36. Shiroiwa T, Sung YK, Fukuda T et al. International survey on willingnessto-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422–437
37. Ягудина РИ, Куликов АЮ, Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. Фармакоэкономика 2011; 4(1): 7-12 [Yagudina RI, Kulikov AYU, Nguyen T. Opredeleniye «poroga gotovnosti platit’» v Rossii, v Yevropeyskikh stranakh i v stranakh SNG. Farmakoekonomika 2011; 4(1): 7-12]
38. Ягудина РИ, Серпик ВГ. Методологические основы фармакоэкономического моделирования. Фармакоэкономика, теория и практика 2016; 4(1): 13-18. [Yagudina RI, Serpik VG. Methodological issues of pharmacoeconomic modeling. Pharmacoeconomics: theory and practice 2016; 4(1):13-18]
39. Bolasco P. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review. Clin Cases Miner Bone Metab 2009;6(3):210–219
40. Llach F, Velasquez-Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38 Suppl. 5: 20-33
41. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
42. Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transpl 2004;19:1174-1181
43. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456
44. Nuijten M, Andress DL, Marx SE, Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009;25:1221-1234
45. Roggeri DP, Cozzolino M, Mazzaferro S et al. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. Int J Nephrol Renovasc Dis 2015; 8: 1–6. doi: 10.2147/IJNRD.S72011
46. Manjarres L, Sanchez P, Cabezas MC et al. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. BMC Health Serv Res 2016 Aug 26;16:443. doi: 10.1186/s12913-016-1671-4
47. Gal-Moscovici A, Sprague SM. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig 2007;27(2):105-113
48. Cozzolino M, Ketteler M, Martin KJ et al. Paricalcitolor cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant 2014;29(4):899-905. doi: 10.1093/ndt/gfu011. Epub 2014 Feb 4
49. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592
50. Khan AM, Chirinos JA, Litt H et al. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012; 7: 2017–2022
51. Lee GH, Benner D, Regidor DL et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38–44
52. Tentori F, Hunt WC, Stidley CA et al. for the Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858–1865
53. Nuijten M, Andress DL, Marx SE et al. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig 2010;30(8):545-557. doi: 10.2165/11536310-000000000-00000
54. Menezes FG, Abreu RM, Itria A. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective. J Bras Nefrol. 2016;38(3):313-319. doi: 10.5935/0101-2800.20160048
55. Nuijten M, Roggeri DP, Roggeri A et al. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected]. Clin Drug Investig 2015;35(4):229-238. doi: 10.1007/s40261-014-0264-4
56. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-254
57. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-583
58. Shireman TI, Almehmi A, Wetmore JB et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56(6):1108-1116. doi: 10.1053/j.ajkd.2010.07.012
59. Eandi M, Pradelli L, Iannazzo S et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;28(11):1041-1054. doi: 10.2165/11538600-000000000-00000
60. Iannazzo S, Carsi M, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Appl Health Econ Health Policy 2012;10(2):127-138. doi: 10.2165/11597980-000000000-00000
61. Belozeroff V, Chertow GM, Graham CN et al. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value Health 2015;18(8):1079-1087. doi: 10.1016/j.jval.2015.08.007
62. Ray JA, Borker R, Barber B et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008;11(5):800–808
63. Battistella M, Richardson RM, Bargman JM, Chan CT. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with endstage renal disease. Clin Nephrol 2011;76(2):99-103
64. Tanaka M, Yoshida K, Fukuma S. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. PLoS One 2016; 11(10): e0164865. Published online 2016 Oct 20. doi: 10.1371/journal.pone.0164865
65. Block GA, Bushinsky DA, Cunningham J et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017;317(2):146-155. doi: 10.1001/jama.2016.19456
66. Fukagawa M, Yokoyama K, Shigematsu T et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 2017. pii: gfw408. doi: 10.1093/ndt/gfw408
67. Achinger SA, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia a risk factor in dialysis patients? J Am Soc Nephrol 2006;17(12 Suppl 3):255-261
68. Ketteler M, Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017;92(1):26-36. doi: 10.1016/j.kint.2017.04.006
69. Новокшонов КЮ, Карелина Ю, Земченков А.Ю и др. Результаты скрининга на маркеры минеральных и костных нарушений при хронической болезни почек среди диализных пациентов Северо-Западного Федерального округа. Нефрология 2016;20(1):36-50. [Novokshonov K, Karelina J, Zemchenkov AY et al. Chronic kidney disease mineral and bone disorder markers in screening study among dialysis patients in north-west Federal region of Russia. Nephrology (Saint-Petersburg). 2016;20(1):36-50]
70. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2017;69(3)(suppl 1):1-688
71. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calciumbased versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and metaanalysis. Lancet 2013;382:1268–1277. Doi: 10.1016/S0140-6736(13)60897-1
72. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438–441
73. Mudge DW, Johnson DW, Hawley CM et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011;12:20. doi: 10.1186/1471-2369-12-20
74. Ketteler M, Rix M, Fan S et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3(4): 1125–1130
75. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calciumand aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55(1):299–307
76. Manns B, Klarenbach S, Lee H et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22(10):2867-2878
77. Bernard L, Mendelssohn D, Dunn E et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ 2013;16(1):1–9
78. Suki WN. Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr 2008;18(1):91–98
79. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis (5th ed.). Faculty Bookshelf 2015; 23
80. Floege J, Covic AC, Ketteler M et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015;30(6):1037-1046. doi: 10.1093/ndt/gfv006
81. Gutzwiller FS, Pfeil AM, Ademi Z et al. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. Pharmacoeconomics 2015;33(12):1311-1324. doi: 10.1007/s40273-015-0320-9
82. Park H, Rascati KL, Keith MS. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations. J Manag Care Spec Pharm 2015; 21(6):507-514
83. Schneider R, Kolios G, Koch BM et al. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. Surgery 2010;148(6):1091-1099. doi: 10.1016/j.surg.2010.09.009
84. Komaba H, Moriwaki K, Goto S. et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis 2012;60(2):262-271. doi: 10.1053/j.ajkd.2011.12.034
85. Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery 2008;144(6):915-918; discussion 919. doi: 10.1016/j.surg.2008.07.026
86. Chow TL, Chan TT, Ho YW, Lam SH. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg 2007;142(7):644-648
87. Belozeroff V, Cooper K, Hess G, Chang CL. Healthcare use and costs before and after parathyroidectomy in patients on dialysis. BMC Health Serv Res 2013;13:248. doi: 10.1186/1472-6963-13-248.
88. Герасимчук РП, Кондаков СБ, Земченков АЮ и др. Коррекция умеренного вторичного гиперпаратиреоза местными инъекциями препаратов витамина D в паращитовидные железы. Нефрология и диализ 2015; 17(1): 58-66 [Gerasimchuk RP, Kondakov SB, Zemchenkov AYu et al. The correction of secondary hyperthyroidism by local vitamin D injection in parathyroid glands. Nephrology and dialysis 2015; 17(1): 58-66]
89. Земченков АЮ, Герасимчук РП, Новокшонов КЮ и др. Сравнительный анализ эффективности паратиреоидэктомии и местных инъекций активаторов рецепторов витамина D в паращитовидные железы. Нефрология 2016; 20(4):80-92 [Zemchenkov AY, Gerasimchuk RP, Novokshonv KY et al. Comparative analysis of the parathyroidectomy and local vitamin D receptor activator injections into parathyroid glands. Nephrology (Saint-Petersburg) 2016;20(4):80-92]
Review
For citations:
Vishnevskii K.A., Zemchenkov A.Yu., Gerasimchuk R.P., Rumyantsev A.Sh., Smirnov A.V., Partsernyak S.A., Maryutin P.V. PHARMACOECONOMIC OF CKD-MBD TREATMENT: LITERATURE REVIEW. Nephrology (Saint-Petersburg). 2018;22(1):38-51. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-1-38-51
Views:
1659
Email this article 